lung cancer

Johnson & Johnson (NYSE:JNJ) just hit a Golden Cross, a classic bullish technical pattern that signals potential long-term upside. The stock's 50-day simple moving average crossed above its 200-day simple moving average, often seen as a sign of strengthening momentum. While the charts suggest...

Thursday, the FDA approved Amgen Inc’s (NASDAQ:AMGN) Imdelltra (tarlatamab-dlle) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.  Imdelltra has received...

In a recent development, the American Cancer Society has widened its lung cancer screening guidelines. This change could potentially result in an additional five million U.S. adults being screened each year. What Happened: As reported by Fortune, the American Cancer Society has revised its lung...

Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%. The two NMEs that were okayed in November include Provention Bio, Inc.’s...

The FDA advisory committee voted against the full approval of Eli Lilly And Co's (NYSE: LLY) lung cancer treatment over concerns that the clinical trial was conducted only in China and that its results did not apply to U.S. patients. The monoclonal antibody treatment sintilimab...

Merck KGaA (OTC: MKGAF) and GlaxoSmithKline Plc (NASDAQ: GSK) have ended their $4 billion collaboration on cancer treatment, bintrafusp alfa. Merck said the move was a mutual decision, primarily due to disappointing lung cancer trial data, adding that GSK made no...

Aileron Therapeutics Inc (NASDAQ: ALRN) presented new clinical data at the European Society of Medical Oncology (ESMO21) Virtual Congress 2021 for ALRN-6924, a chemoprotective agent.  Aileron is developing ALRN-6924 to selectively protect healthy cells in patients with cancers...

CureVac NV (NASDAQ: CVAC) disclosed among the COVID-19 vaccine highlights that €465 million oncology partnership with Boehringer Ingelheim had been terminated. CureVac and Boehringer had been working to develop the mRNA cancer vaccine candidate since 2014, when CureVac...

Oncocyte Corporation's (NASDAQ: OCX) Q2 revenues were $2.03 million, compared to $143,000 in Q2 FY20 and beating consensus of $1.57 million. Most revenues were attributable to tech transfer under a December licensing deal with Burning Rock Biotech for Oncocyte's DetermaRx lung...

BeyondSpring Inc (NASDAQ: BYSI) is trading over 300% up during premarket in reaction to topline data from DUBLIN-3 Phase 3 trial evaluating plinabulin in combination with docetaxel. The trial includes patients 2nd/3rd Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Wild Type. The data...

Lixte Biotechnology Holdings Inc (NASDAQ: LIXT) has announced that its lead compound, LB-100, a protein phosphatase 2A (PP2A) inhibitor, was reported to enhance the effectiveness of elements of standard therapy in models of small cell lung cancer (SCLC). Dr. Ravi Salgia is the paper...

Iovance Biotherapeutics Inc (NASDAQ: IOVA) has announced clinical data for its tumor-infiltrating lymphocyte (TIL) therapy LN-145 in patients with metastatic non-small cell lung cancer (mNSCLC).  The cohort enrolled patients that had progressed on prior immune checkpoint...

The FDA has granted Breakthrough Therapy designation to Mirati Therapeutics Inc's (NASDAQ: MRTX) adagrasib in non-small cell lung cancer (NSCLC) patients with the KRAS-G12C mutation. The decision was based on preliminary results from the Phase 1/2 KRYSTAL-01 trial in...

The European Commission (EC) has approved Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Libtayo (cemiplimab) for two additional indications - basal cell carcinoma (BCC) and non-small cell lung cancer with over 50% PD-L1 expression. BCC (...

AstraZeneca Plc’s (NASDAQ: AZN) has announced updated results from the PACIFIC Phase 3 trial of Imfinzi (durvalumab), showing survival benefit at five years in patients with unresectable Stage III non-small-cell lung cancer (NSCLC) who had not progressed following concurrent...